HAI-Floxuridine, or Liver-Tx, Combined With 2nd Line Chemotherapy Versus 2nd Line Chemotherapy Alone for Patients With Colorectal Livermetasteses and Heavy Tumour Burden.

• Status: Recruiting
• Trial end date: 2026-05-01

Summary

Patients with colorectal livermetasteses and heavy tumour burden and progression on 1st line chemotherapy have no other available treatment in Norway today other than 2nd line chemotherapy. The Investigators will randomize patients younger than 70 yrs old to HAI-floxuridine, or liver-Tx, in addition to 2nd line chemotherapy versus 2nd line chemotherapy alone. Patients 70yrs and older will be randomized to HAI-floxuridine and 2nd line chemotherapy versus 2nd line chemotherapy alone. Primary endpoint being overall survival at 2yrs in the different arms.

• Phase: Phase 2

Details

• Lead Sponsor: Oslo University Hospital
• Treatments: Floxuridine